Drug Database
Back to search

Finland· FI-REL-REL44749

Xydalba

A dalbavancin product containing dalbavancin, registered in Finland by AbbVie Deutschland GmbH&Co.KG. The same ATC class is registered in 16 of our 19 countries.

ATC J01XA04

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedXydalbaATCJ01XA04REGISTER NO.FI-REL-REL44749PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dalbavancinAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dalbavancin is registered in 16 of 19 countries.

Countries holding a registration under ATC J01XA04 (dalbavancin), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose
Search dalbavancin products by name

Dalbavancin · ATC J01XA04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Dalbavancin
Manufacturer
AbbVie Deutschland GmbH&Co.KG
Country
Finland (FI)
ATC code
J01XA04
ATC class
Dalbavancin
Defined daily dose
1.5 g, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for dalbavancin.

Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dalbavancin against other medicinesHow interaction checks work

Dalbavancin · interactions on record

7 records

  • 7 moderate

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • Levonorgestrel and ethinylestradiolG03AA07moderate
  • Desogestrel and ethinylestradiolG03AA09moderate
  • Drospirenone and ethinylestradiolG03AA12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dalbavancin in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dalbavancin products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Dalbavancin, Dalbavancin Accord
  • Germany · Dalbavancin Accord, Dalbavancin Baxter
  • Denmark · Dalbavancin Adalvo, Dalbavancin Teva
  • Spain · Dalbavancin Dr. Reddys, Dalbavancina Accord
  • France · Dalbavancine Accord, Dalbavancine Reddy Pharma
  • United Kingdom (Northern Ireland) · Dalbavancin Accord, Dalbavancin Reig Jofre Uk
  • Greece · Bavalda, Dalbavancin Accord
  • Iceland · Xydalba
  • Italy · Dalbavancina Accord, Dalbavancina Dr. Reddy’s
  • Liechtenstein · Xydalba
  • Malta · Bavalda, Dalbavancin Adalvo
  • Norway · Dalbavancin Tillomed, Xydalba
  • Poland · Dalbavancin Accord, Dalbavancin Reig Jofre
  • Portugal · Dalbavancina Anfarm
  • Sweden · Dalbavancin Accord, Dalbavancin Bioglan
  • Slovakia · Dalbavancin Adalvo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a51a6258-5673-42c3-9819-8eb267415ea4
GET /v1/drugs/a51a6258-5673-42c3-9819-8eb267415ea4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "1.5",
  "form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
  "route": "Laskimoon",
  "ddd_unit": "g",
  "strength": "500 mg",
  "atc_label": "dalbavansiini",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/14/986/001",
  "fimea_rel_id": "REL44749",
  "authorised_at": "2015-02-19"
}
API referenceMCP serverPlans

See everything about dalbavancin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console